News
13hon MSN
Akero Therapeutics Inc. (NASDAQ:AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced that ...
Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback